27888-44-4 Usage
General Description
N-behenoyl-D-erythro-sphingosine, also known as C24 ceramide, is a long-chain ceramide molecule that consists of a sphingosine base linked to a behenic acid fatty acid chain. Ceramides are important components of the lipid bilayer in cell membranes and are involved in various cellular processes, including cell signaling, proliferation, and apoptosis. N-behenoyl-D-erythro-sphingosine has been found to have potential therapeutic effects, including anti-cancer properties and the ability to improve skin barrier function. It is also being studied for its role in neurodegenerative diseases and inflammatory disorders. Overall, N-behenoyl-D-erythro-sphingosine is a biologically important molecule with promising therapeutic potential.
Check Digit Verification of cas no
The CAS Registry Mumber 27888-44-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,7,8,8 and 8 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 27888-44:
(7*2)+(6*7)+(5*8)+(4*8)+(3*8)+(2*4)+(1*4)=164
164 % 10 = 4
So 27888-44-4 is a valid CAS Registry Number.
27888-44-4Relevant academic research and scientific papers
Ceramide compound and application
-
Paragraph 0034-0036; 0039, (2017/07/06)
The invention relates to a ceramide compound; in the structural general formula, m=2-12; n=0-20. The ceramide compound has significant pseudo neural growth factor activity, and is the small molecule compound capable of passing through blood-brain barrier. The structural general formula is shown as Figure.
Structure-activity relationship of α-galactosylceramides against b16- bearing mice
Morita,Motoki,Akimoto,Natori,Sakai,Sawa,Yamaji,Koezuka,Kobayashi,Fukushima
, p. 2176 - 2187 (2007/10/02)
Agelasphin-9b, (2S,3S,4R)-1-O-(α-D-galactopyranosyl)-16-methyl-2-[N- ((R)-2-hydroxytetracosanoyl)-amino]-1,3,4-heptadecanetriol, is a potent antitumor agent isolated from the marine sponge Agelas mauritianus. Various analogues of agelasphin-9b (a lead compound) were synthesized, and the relationship between their structures and biological activities was examined using several assay systems. From the results, KRN7000, (2S,3S,4R)-1-O-(α- D-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4-octadecanetriol, was selected as a candidate for clinical application.
